Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
With
Chugai Pharmaceutical
Age
0–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Children less than (\<) 12 years of age, with allowance for participants 12 to 17 years of age who weigh \<40 kilograms (kg) (Cohort A only); and participants \<2 years of age will be allowed to participate only after the protocol-defined interim data review criteria are met (Cohort A only)
Diagnosis of congenital hemophilia A of any severity and documented history of high-titer inhibitor (that is \[i.e.\], greater than or equal to \[\>/=\] 5 bethesda units \[BU\])
Requires treatment with bypassing agents
Adequate hematologic, hepatic, and renal function
You may not be if
Inherited or acquired bleeding disorder other than hemophilia A
Ongoing (or planning to receive during the study) immune tolerance induction (ITI) therapy or prophylaxis treatment with FVIII
Previous (in the past 12 months) or current treatment for thromboembolic disease or signs of thromboembolic disease
Other disease that may increase risk of bleeding or thrombosis
History of clinically significant hypersensitivity associated with monoclonal antibody therapy or components of the emicizumab injection
Known infection with human immunodeficiency virus (HIV) or hepatitis B or C virus
Use of systemic immunomodulators at enrollment or planned use during the study period
Planned surgery (excluding minor procedures such as tooth extraction or incision and drainage) during the study
Inability (or unwillingness by caregiver) to receive (allow receipt of) blood or blood products (or any standard-of-care treatment for a life-threatening condition)
Participants who are at high risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA), in the investigator's judgement
